154 Financial Disclosure JMG receives research support from and is a consultant with Abbott. Open Access This article is distributed under the terms of the Crea- tive Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. References 1. Jemal A, Siegel R, Xu R, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. 2. Ries LAG EM, Kosary CL, Hankey BF, Miller MBA, Clegg L,, al. e. SEER cancer statistics review, 197–2000. Bethesda, (MD): National Cancer Institute. 2003. 3. Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer. 2006;107:2949–57. 4. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724–31. 5. Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920–6. 6. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762–9. 7. Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, et al. H y p o g o n a d i s m i n m a l e p a t i e n t s w i t h c a n c e r. C a n c e r. 2006;106:2583–91. 8. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100:851–8. 9. Todd BD. Pancreatic carcinoma and low serum testosterone; a correlation secondary to cancer cachexia? Eur J Surg Oncol. 1988;14:199–202. 10. Chlebowski RT, Heber D. Hypogonadism in male patients with meta- static cancer prior to chemotherapy. Cancer Res. 1982;42:2495–8. 11. Fleishman SB, Khan H, Homel P, Suhail MF, Strebel-Amrhein R, Mohammad F, et al. Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. J Clin Oncol. 2010;28:5054–60. 12. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond). 1999;97:215–23. 13. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2:862–71. 14. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace Jr D, Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003;97:1211–6. 15. Tsigos C, Papanicolaou DA, Kyrou I, Raptis SA, Chrousos GP. Dose-dependent effects of recombinant human interleukin- 6 on the pituitary-testicular axis. J Interferon Cytokine Res. 1999;19:1271–6. 16. Watson ME, Newman RJ, Payne AM, Abdelrahim M, Francis GL. The effect of macrophage conditioned media on Leydig cell func- tion. Ann Clin Lab Sci. 1994;24:84–95. J Cachexia Sarcopenia Muscle (2012) 3:149–155 17. Afane M, Dubost JJ, Sauvezie B, Issoual D, Dosgilbert A, Grizard G, et al. Modulation of Leydig cell testosterone production by secretory products of macrophages. Andrologia. 1998;30:71–8. 18. Turnbull AV, Rivier C. Inhibition of gonadotropin-induced testoster- one secretion by the intracerebroventricular injection of interleukin-1 beta in the male rat. Endocrinology. 1997;138:1008–13. 19. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313–8. 20. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo- controlled Moscow study. Clin Endocrinol (Oxf).73:602-12. 21. Cutolo M, Balleari E, Giusti M, Intra E, Accardo S. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum. 1991;34:1–5. 22. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos- Flier E, et al. Role of leptin in the neuroendocrine response to fasting. Nature. 1996;382:250–2. 23. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341:879–84. 24. Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003;111:1409–21. 25. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, et al. Recombinant human leptin in women with hypothalamic amen- orrhea. N Engl J Med. 2004;351:987–97. 26. Smiechowska J, Utech A, Taffet G, Hayes T, Marcelli M, Garcia JM. Adipokines in patients with cancer anorexia and cachexia. J Investig Med. 2010;58:554–9. 27. Furuta M, Funabashi T, Kimura F. Intracerebroventricular adminis- tration of ghrelin rapidly suppresses pulsatile luteinizing hormone secretion in ovariectomized rats. Biochem Biophys Res Commun. 2001;288:780–5. 28. Fernandez-Fernandez R, Tena-Sempere M, Navarro VM, Barreiro ML, Castellano JM, Aguilar E, et al. Effects of ghrelin upon gonadotropin-releasing hormone and gonadotropin secretion in adult female rats: in vivo and in vitro studies. Neuroendocrinology. 2005;82:245–55. 29. Fernandez-Fernandez R, Tena-Sempere M, Aguilar E, Pinilla L. Ghrelin effects on gonadotropin secretion in male and female rats. Neurosci Lett. 2004;362:103–7. 30. Sirotkin AV, Chrenkova M, Nitrayova S, Patras P, Darlak K, Valenzuela F, et al. Effects of chronic food restriction and treatments with leptin or ghrelin on different reproductive parameters of male rats. Peptides. 2008;29:1362–8 31. Kluge M, Schussler P, Uhr M, Yassouridis A, Steiger A. Ghrelin suppresses secretion of luteinizing hormone in humans. J Clin Endocrinol Metab. 2007;92:3202–5. 32. Lanfranco F, Bonelli L, Baldi M, Me E, Broglio F, Ghigo E. Acylated ghrelin inhibits spontaneous luteinizing hormone pulsa- tility and responsiveness to naloxone but not that to gonadotropin- releasing hormone in young men: evidence for a central inhibitory action of ghrelin on the gonadal axis. J Clin Endocrinol Metab. 2008;93:3633–9. 33. Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manage. 1994;9:126–31. 34. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, et al. Endocrine consequences of long-term intra- thecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–22.